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BACKGROUND͗Acromegaly is a rare disease, the incidence and prevalence of which are underestimated
due to many factors such as late or missed diagnosis and paucity of registries.
AIM͗To collect in a large database (AcromER) all  available data on acromegalic patients of Emilia
Romagna (ER) over a period of ϰϳ years.
METHODS͗Retrospective, observational, multicenter study involving adult (хϭϴ years) acromegalic
patients followed in ϭϮ Endocrine Clinics of ER in the period ϭϵϳϬ-ϮϬϭϳ. The study was approved by the
Ethical  Committee  of  the  ϭϮ  clinical  centers.  Main  information  on  diagnosis,  treatment  and
comorbidities of each patient were collected in a standardized CRF. The same patient who was followed
in two or more centers was considered once.
RESULTS͗A total of ϰϲϳ patients [ϮϴϬ F (ϱϵ,ϵϱй), median age at diagnosis of ϰϵ years (ϭϴ-ϴϱ), median
follow-up: ϭϮ,ϵ years΁ were included. Estimated incidence and prevalence were Ϭ.ϰϵ per year and ϭϭ.Ϯ
cases  per  ϭϬϬ.ϬϬϬ.  Somatic  changes  (ϳϬ,Ϯй),  headache  (ϯϯ,ϴй),  snoring  (Ϯϰ,ϴй),  menstrual
abnormalities in females (ϮϬй), hyperhidrosis (ϭϱ,ϲй), and visual impairment (ϭϰ,ϱй) were the most
frequent symptoms at diagnosis. Micro and macroadenomas were ϯϬ,ϴй and ϲϵ,Ϯй, respectively. The
age at diagnosis was significantly lower in patients with macro than in those with microadenomas
(pфϬ,Ϭϱ). Surgery was the first line therapy in ϯϲϳ patients (ϳϴ,ϲй), medical therapy in ϭϬϬ (Ϯϭ,ϰй).
Surgery resulted in persistent disease remission in ϱϮй of cases, in transient remission with subsequent
relapse  in  ϭϬй,  and  in  no  cure  in  ϯϴй.  Remission  occurred  more  frequently  in  micro  than
macroadenomas (pсϬ,ϬϬϬϭ) and in trans-sphenoidal endoscopic approach (pсϬ,ϬϬϮ). Somatostatin
analogues (SSA) were used after surgery in ϴϬй of cases, dopamine agonists (DA) in ϲй, and DAнSSA in
ϭϰй. SSAs, DA, and DAнSSAs were used as first line medical therapy in ϴϱй, ϰй, and ϭϬй of cases. At
last follow-up ϰϵй of patients were cured, ϯϵй had controlled disease, and ϭϮй uncontrolled disease.
With exception of cancer, all the other comorbidities were more frequent in patients treated with first
line medical therapy compared to surgery or surgeryнmedical therapy (pфϬ,Ϭϱ). The use of Pegvisomant
was more frequent in tertiary than in smaller endocrinological centers (pсϬ,ϬϬϬϭ).
CONCLUSIONS͗ This  is  the first  Italian  epidemiological  analysis  coming from an endocrinological
network  covering  the  whole  area  of  an  Italian  region.  In  the  single  regional  setting  of  ER  the
management of acromegaly and the treatments outcomes resulted to be aligned with other European
reports. Furthermore, these data speak in favor of homogeneity of acromegaly management in the
Endocrine Clinics of ER.
